Yarrow Bioscience, Inc. entered into an exchange agreement with an existing stockholder to swap 133,290 shares of common stock for pre-funded warrants to purchase the same number of shares at $0.0001 per share. The transaction closed on July 29, 2026, resulting in 2,669,788 outstanding shares and 25,914,530 outstanding pre-funded warrants. This corporate action is not material to investors as it involves a routine exchange with no change in control or significant capital raise. The company operates in the biotechnology industry.
